Lagevrio (Eua)

Molnupiravir is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by adults 18 years of age and older who have had mild to moderate symptoms for no more than 5 days and are not hospitalized. To receive this product you must also be at high... Molnupiravir works by preventing the growth of the virus that causes COVID-19. More information about molnupiravir is available from the FDA Fact Sheet for Patients, Parents, and Caregivers for Emergency Use. There is limited information about how safe and effective molnupiravir is for treating COVID-19. Study results show that molnupiravir may help people who have coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of molnupiravir, and it is always the responsibility of treating practitioners to exercise independent judgement in making care decisions. View More Info